ZANTAC. TAKING THE STING OUT OF NSAIDs.



NSAIDs claim around 3,000 lives a year in the UK alone.[1] Patients with a history of ulcer disease being at greatest risk of life-threatening complications.[2]

However, NSAIDs also keep a great many arthritis sufferers mobile.

So, let Zantac help put an end to this sting in the tail. It's an effective treatment. Successfully healing both duodenal and gastric ulcers.[3] But, used as prophylaxis, Zantac can actually prevent NSAID-associated duodenal ulcers.[4] In fact it's the only H_2 licensed to do this.[5]

Give your high risk NSAID patients Zantac. And you can still give them the freedom of movement.

Zantac
RANITIDINE HCl

PRESCRIBING INFORMATION:
Indications Duodenal ulcer, benign gastric ulcer, ulcers associated with non-steroidal anti-inflammatory drugs (NSAIDs), prevention of NSAID-associated duodenal ulcer, oesophageal reflux disease, severe oesophagitis, long-term management of healed oesophagitis, chronic episodic dyspepsia. **Dosage** *Adults:* Duodenal ulceration and gastric ulceration: A single 300mg dose at bedtime or 150mg twice daily in the morning and evening for four weeks. In duodenal ulcers, 300mg twice daily produces higher healing rates at four weeks. Continued maintenance treatment of 150mg at bedtime is recommended for patients with a history of recurrent ulceration. Ulcers following non-steroidal anti-inflammatory drug therapy or associated with continued non-steroidal anti-inflammatory drugs: 150mg twice daily for up to eight weeks. Prevention of NSAID-associated duodenal ulcer: 150mg twice daily concomitantly with NSAID therapy. Chronic episodic dyspepsia: 150mg twice daily for six weeks, investigate early relapsers and non-responders. Oesophageal reflux disease: 300mg at bedtime or 150mg twice daily for up to eight weeks. Moderate to severe oesophagitis: 150mg four times daily for up to twelve weeks (see data sheet for full dosage instructions). Long-term treatment of healed oesophagitis: 150mg twice daily. *Children:* Oral dose for peptic ulcer: 2mg/kg to 4mg/kg, twice daily to a maximum of 300mg per day. **Contra-indications** Patients with known hypersensitivity to ranitidine. **Precautions** In patients in whom sodium restriction is indicated, care should be taken when administering sodium-containing Effervescent Tablets. Exclude the possibility of malignancy in gastric ulcer before instituting therapy, especially in middle-aged patients with new or recently changed dyspeptic symptoms. Regular supervision of patients taking NSAIDs concomitantly with Zantac is recommended, especially if elderly. Protects against NSAID-associated ulceration in duodenum and not in stomach. Reduce dosage in the presence of severe renal failure (see data sheet). Avoid in patients with history of porphyria. Effervescent Tablets contain aspartame, use with caution in patients with phenylketonuria. Like other drugs, use during pregnancy and lactation only if strictly necessary. **Side effects** Headache, dizziness, skin rash, occasional hepatitis, rarely arthralgia, myalgia. Rarely, reversible mental confusion states, usually in very ill or elderly patients. Rare cases of leucopenia and thrombocytopenia, usually reversible, agranulocytosis and pancytopenia. Hypersensitivity reactions, anaphylactic shock. Rare cases of breast symptoms in men. As with other H_2-receptor antagonists rare cases of bradycardia, A-V block and asystole (see data sheet). **Presentations** Zantac 150 Tablets each containing 150mg ranitidine HCl, (Product licence number 10949/0042, 60 tablets £27·89); Zantac 300 Tablets each containing 300mg ranitidine HCl (Product licence number 10949/0043, 30 tablets £27·43); Zantac Effervescent Tablets each containing 150mg ranitidine HCl and 14·3mEq sodium, (Product licence number 0004/0392, 60 tablets £27·89); Zantac Effervescent Tablets each containing 300mg ranitidine HCl and 20·8mEq sodium (Product licence number 0004/0393, 30 tablets £27·43), Zantac Syrup each 10ml dose containing 150mg ranitidine HCl (Product licence number 10949/0108, 300ml bottle £22·32). **Product licence holders** Glaxo Operations UK Limited, Greenford, Middlesex UB6 0HE. Glaxo Pharmaceuticals UK Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT. POM Zantac is a Glaxo trade mark. Further information is available on request from: Glaxo Laboratories Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT. Telephone 081-990 9444. June 1994.

References
1. Hayllar J, Macpherson A, Bjarnason I. Drug Safety 1992; 7(2): 86-105. 2. Rodriguez LAG, Jick H. The Lancet 1994. Vol 343: 769-772. 3. Lancaster-Smith ML, Jaderberg ME, Jackson DA. Gut 1991; **32**: 252-255. 4. Robinson MG, Griffin JW, Bowers J *et al.* Dig Dis Sci 1989; **34**(3): 424-428.
5. Zantac Data Sheet.

Glaxo Laboratories Limited



Look, no reflux

(no associated bloating or belching)

Prepulsid heals oesophagitis by acting where it's needed – at the oesophagus.[1] Prepulsid relieves heartburn as effectively as ranitidine and also offers relief of associated bloating and belching.

A physiological approach

AFTER ANTACIDS

Prepulsid™

cisapride

PRESCRIBING INFORMATION Indications: GASTRO-OESOPHAGEAL REFLUX DISEASE: Treatment of symptoms and healing of mucosal lesions; maintenance treatment of reflux oesophagitis. DYSPEPSIA: Treatment of symptoms such as epigastric pain, early satiety, bloating and belching where organic disease has been excluded. IMPAIRED GASTRIC EMPTYING: Relief of the symptoms such as epigastric pain, early satiety, anorexia, bloating and nausea associated with impaired gastric emptying secondary to systemic sclerosis and autonomic neuropathy of diabetes. Dosage and Administration: Adults and children twelve years and over: Take 15 minutes before food. GORD/LOI: 20mg Prepulsid bd (before breakfast and at bedtime) or 10mg Prepulsid qds (before meals and at bedtime). If symptoms can be treated with a fourth 10mg dose at bedtime) for 12 weeks. For long term maintenance therapy, 20mg once daily (at bedtime) or 10mg twice daily (before breakfast and at bedtime) increasing to 20mg twice daily as patients whose before were inadequately severe DYSPEPSIA: 10mg Prepulsid tid. Usual course of treatment is 4 weeks. IMPAIRED GASTRIC EMPTYING: 10mg Prepulsid tid or qd. An initial course of 4 weeks is recommended but longer treatment may be required. CHILDREN: Not recommended in children under 12. ELDERLY: As for adults, but monitor response. ABNORMAL RENAL/LIVER FUNCTION: Initially dose should be halved. Contra-indications: Pregnancy; patients in whom gastrointestinal stimulation might be dangerous; hypersensitivity to Prepulsid. Warnings: Not recommended whilst breast feeding. Drug Interactions: Absorption from the stomach of concomitantly administered drugs may be diminished, whereas absorption of drugs from the small intestine may be accelerated. For drugs that require careful individual titration e.g. anticonvulsants, it may be useful to measure plasma concentrations. In patients receiving anticoagulants, check prothrombin time as it may be [illegible] Interactions with histamine H2-receptor antagonists and alcohol may be accelerated when given with [illegible] by anticholinergic drugs. **Side Effects:** [illegible] Overdosage: Should severe [illegible] effects include headaches and lightheadedness. Reports of hyperprolactinaemia, galactorrhoea, extrapyramidal effects and increased urinary frequency have been received. Reversible reversible liver function abnormalities have been reported - causal relationship not established. Overdosage: Treatment includes activated charcoal, close observation and general supportive measures. Presentation: Prepulsid Tablets: packs of 100 tablets containing 10mg cisapride. Prepulsid Suspension: 500ml bottles containing 5mg/5ml cisapride. Storage: Prepulsid Tablets: store at room temperature [illegible] Prepulsid Suspension: store at room temperature [illegible] 02420157. PL [illegible] Janssen, High Wycombe, Bucks HP11 1PD. Basic NHS Cost: 120 tablets - [illegible] Legal Category: POM.

1. Janssens J. Effect of cisapride on [illegible] motility. In Johnson A.G., Lux G. Eds. Progress in the treatment of oesophageal motility disorders. Amsterdam, Excerpta Medica, 1988;11-18. 2. [illegible] regimens of cisapride in the treatment of reflux oesophagitis. Aliment Pharmacol Ther 1993; 7: 409-415.

[illegible] DECEMBER 1994

KEEP ACID WHERE IT WORKS NOT WHERE IT HURTS



Sadly, you're powerless over the scars which acid rain has left on the forests of Europe.

But if you know the true nature of the problem there's a lot you can do for the victims of acid reflux.

It's a little known fact that nearly 80% of reflux patients don't suffer from excess acid,[1,2] they suffer from acid in the wrong place.

So doesn't it make sense to use a reflux treatment which keeps acid where it works and not where it hurts?

Gaviscon works by forming a soothing alginate barrier

Prescribing Information. Liquid Gaviscon. Active Ingredients: Sodium alginate BP 500mg, sodium bicarbonate Ph.Eur. 267mg and calcium carbonate Ph.Eur. 160mg per 10ml dose. **Indications:** Heartburn, including heartburn of pregnancy, dyspepsia associated with gastric reflux, hiatus hernia and reflux oesophagitis. **Contra-Indications:** None known. **Dosage and Administration:** Adults and children over 12: 10-20ml liquid, after meals and at bedtime. Children 6-12: 5-10ml liquid after meals and at bedtime. **Note:** 10ml liquid contains 6.2mmol sodium. **Basic NHS Cost:** 500ml liquid £2.70. **PL:** 44/0058 Liquid Gaviscon, 44/0140 Liquid Gaviscon Peppermint Flavour. **Legal Category:** GSL. (PO). **Gaviscon Tablets. Active Ingredients:** Alginic acid BP 500mg, sodium bicarbonate Ph.Eur. 170mg, dried aluminium hydroxide gel BP 100mg, magnesium trisilicate Ph.Eur. 25mg per tablet. In a sugar free flavoured base containing calcium carbonate (40mg) and saccharin. **Indications:** Heartburn, including heartburn of pregnancy, dyspepsia associated with gastric reflux, hiatus hernia and reflux oesophagitis. **Contra-Indications:**



which prevents acid from rising into the oesophagus, bringing rapid relief to 4 out of 5 reflux patients.[3,4,5]

So to keep acid in its natural environment, make Gaviscon your first choice in reflux.

GAVISCON

liquid: **sodium alginate BP, sodium bicarbonate Ph.Eur., calcium carbonate Ph.Eur.**
tablets: **alginic acid BP, sodium bicarbonate Ph.Eur., aluminium hydroxide BP, magnesium trisilicate Ph. Eur.**

Keeps acid in its natural environment

None known. **Dosage and Administration:** Adults and children over 12: 1 or 2 tablets after meals and at bedtime. Children 6-12: 1 tablet after meals and at bedtime. **Note:** 1 tablet contains 2.1mmol sodium. Tablets should be thoroughly chewed. **Basic NHS Cost:** 60 tablets £2.25. **PL:** 44/0021 Gaviscon Tablets, 44/0141 Gaviscon Tablets Lemon Flavour. **Legal Category:** GSL. (PO). **Holder of product licences:** Reckitt & Colman Products Limited, Dansom Lane, Hull, HU8 7DS. Gaviscon and the sword and circle symbol are registered trademarks. **Date of preparation:** 20/9/94.

References 1. Ball C.S. *et al.* (1988) *GUT*, Vol. 29 (part 10) A 1449. 2. Cadiot G. *et al.* (1994) *Gastrointest. Res.* **22:** 209-222. 3. Chevrel B. (1980) *J. Int. Med. Res.* **8:** 300. 4. Ward A.E. (1989) *Br. J. Clin. Pract.* **43** (2) Suppl. 66: 52. 5. Williams D.L. *et al.* (1979) *J. Int. Med. Res.* **7:** 551.

RECKITT & COLMAN PRODUCTS

NOW-SPEED WITH ECONOMY

- **Duodenal Ulcer - Up to 98% healing within four weeks** [1-6] *(Range 91-98%)*
- **Reflux Oesophagitis - Up to 95% healing within eight weeks** [7-12] *(Range 85-95%)*
- **Lower total treatment costs per patient symptom free than either omeprazole or ranitidine** [13]

ZOTON*▼ Lansoprazole: Abbreviated Prescribing Information

Presentation: Two tone lilac/purple hard gelatin capsule containing 30 mg Lansoprazole as enteric coated granules. **Indications:** Healing of duodenal ulcer, benign gastric ulcer, and reflux oesophagitis. Also benign peptic lesions including reflux oesophagitis unresponsive to H_2 receptor antagonists. **Dosage and Administration:** Lansoprazole should be administered once daily. *Duodenal ulcer:* 30 mg daily for 4 weeks. *Reflux oesophagitis:* 30 mg daily for 4-8 weeks. *Benign gastric ulcer:* 30 mg daily for 8 weeks. Do not chew or crush capsules. Swallow whole. No dosage adjustment is necessary in the elderly, or patients with renal or hepatic impairment. There is no experience with Lansoprazole in children. Long term treatment cannot be recommended at this time. **Contra-indications:** No known contra-indications to Lansoprazole. **Warnings and Precautions:** As with other anti-ulcer therapies the possibility of malignancy should be excluded when gastric ulcer is suspected. There is no experience with the use of Lansoprazole in pregnancy, and its use should be avoided. Animal studies indicate Lansoprazole is excreted into breast milk, there is no information on secretion into breast milk in humans. Breast feeding should be discontinued if the use of Lansoprazole is considered essential. **Side effects:** Generally transient and self-limiting, including gastro-intestinal disturbances, headache, dizziness, dry mouth, fatigue, rashes, and increases in liver function tests. Arthralgia, peripheral oedema, and haematological changes have been reported rarely. **Legal Category:** POM. **Package Quantities:** *Original Packs:* Blister packs of 56, 28, 14 and 7 (hospital starter pack) capsules. **Product Licence No:** PL 0095/0264. **Cost:** 7's £9.09 (hospital starter pack), 14's £18.18, 28's £33.36, 56's £66.72. Full prescribing information is available on request. Date of preparation: December 1994

REFERENCES 1. Licht, H., *Gastroenterology*, 1990, **98** (5), Pt 2, A78 (21065) 2. Petite, J.P., *Journées Francophones de Pathologies Digestives*, 1991 (20969) 3. Londong, W., *Aliment Pharmacol Therap*, 1991, **53** 245-254 (19818) 4. Hawkey, C.J., *Gut*, 1993, **34** (10), 1458-1462 (20982) 5. Hotz, J., *Aliment Pharmacol Therap*, 1992, **6**, 87-95 (20027) 6. Ekstrom, P., *Scand J Gastroenterol*, 1992, **27** (Supp 190) A34 (20341) 7. Bardhan, K.D., *Gastroenterology*, 1991, Vol **100** (5), A30 (19804) 8. Petite, J.P., Data on file, Lederle Laboratories (20502) 9. Dorsch, E., *Am J Gastroenterol*, 1991, **86** (9), A15 (20009) 10. Robinson, M., *Gastroenterology*, 1992, **102** (4, Pt 2 of 2), A153 (20225) 11. Benhaim, M.C., *Gastroenterology*, 1990, **98** (5), A20 (20164) 12. Hatlebakk, J. G., *Scand J Gastroenterol*, 1993, **28**, 224-228 (20986) 13. Jones, R. and Bosanquet, N. et al, *Br J Med Econ*, 1994, 7, 99-114 (100983)

SECOND GENERATION

ZOTON*▼

PROTON PUMP INHIBITOR

lansoprazole



COLIFOAM

10% hydrocortisone acetate

FIRST CLASS TREATMENT WHICH TRAVELS TO WORK

- Colifoam is highly effective for distal ulcerative colitis.[1]
- The retrograde spread of Colifoam increases with the extent of disease.[2]
- Colifoam is easier to retain than liquid enemas and causes less interference with social, sexual and occupational activities.[1,3]

PRESCRIBED WITH CONFIDENCE FOR OVER 20 YEARS.

PRESCRIBING INFORMATION: Presentation: White odourless aerosol containing hydrocortisone acetate PhEur 10% w/w. **Uses:** Ulcerative colitis, proctosigmoiditis and granular proctitis. **Dosage and administration:** One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed with pack). **Contra-indications, warnings etc:** Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. Although uncommon at this dosage, local irritation may occur. **Pharmaceutical precautions:** Pressurised container containing flammable propellant. Protect from sunlight and do not expose to temperatures above 50°C. Keep away from sources of ignition. Do not pierce or burn even after use. Do not refrigerate, store below 25°C. Keep out of reach of children. For external use only. **Legal category:** POM. **Package quantity & basic NHS cost:** 20.8g canister plus applicator, £7.07. Provides approximately 14 doses. **Product Licence No:** 0036/0021. Further information is available on request from Stafford-Miller Ltd, Broadwater Road, Welwyn Garden City, Herts. AL7 3SP. **Code:** DO2665.

VIRAFERON ABBREVIATED PRESCRIBING INFORMATION

Before prescribing Viraferon please refer to full Data sheet. **Presentation**: 10 million or 25 million IU/vial of Interferon Alfa-2b(rbe) in solution. **Uses**: Treatment of Chronic Active Hepatitis B; reduction of disease activity in Chronic Hepatitis C/ Non-A, Non-B. **Dosage and Administration**: *Chronic Active Hepatitis B:* The recommended dosage is usually in the range of 2.5 million IU to 5.0 million IU/m^2 of body surface area administered subcutaneously three times per week for a period of four to six months. *Chronic Hepatitis C/Non-A, Non-B:* The recommended dose is 3 million IU administered three times a week. Most patients who respond demonstrate improvement in ALT levels within 12-16 weeks. In those patients, therapy should be continued with 3 million IU three times a week for up to 18 months. **Contraindications, Warnings, Precautions, etc.: Contraindications**: A history of hypersensitivity to recombinant Interferon Alfa-2b(rbe) or components of VIRAFERON Injection contraindicates its use; severe pre-existing cardiac disease, severe renal or hepatic dysfunction; epilepsy and/or compromised central nervous system function; chronic hepatitis with advanced decompensated cirrhosis of the liver; chronic hepatitis patients who are being or have been recently treated with immunosuppressive agents excluding short-term corticosteroid withdrawal. Autoimmune hepatitis or history of autoimmune disease, pre-existing thyroid disease not controlled by conventional therapy. **Warnings and Precautions**: Use with caution in patients with a history of pulmonary disease, diabetes mellitus, coagulation disorders or severe myelosuppression. Moderate to severe adverse experiences may require reduction of dosage or termination of VIRAFERON therapy. Patients with chronic Hepatitis B with evidence of decreasing hepatic synthetic function may be at increased risk of clinical decompensation if a flare up of aminotransferases occurs during treatment. Patients with a recent history of cardiovascular events should be closely monitored as adverse cardiovascular events including hypotension and cardiac arrhythmias have been observed. Adequate hydration of patients should be maintained during treatment. Pulmonary infiltrates, pneumonitis and pneumonia, including fatality, have been observed rarely. Reversible CNS effects commonly manifested by confusion have been seen, usually at high doses. Infrequently, patients treated for chronic Hepatitis C/Non-A, Non-B developed thyroid abnormalities, either hypothyroid or hyperthyroid. VIRAFERON may exacerbate pre-existing psoriatic disease. Ocular adverse events have been reported. Concomitant narcotics or sedatives should be administered with caution. Patients taking xanthine derivatives should be monitored and dosage adjusted as necessary. No information is available on the use of interferon in human pregnancy or its effect on human lactation. VIRAFERON should only be given if the benefits clearly

Schering-Plough



Hepatitis C (HCV) is growing faster than cancer as a threat to public health, and it has a similar social impact to HIV. And looking at the figures, it doesn't take too much to figure out why.

In the UK, at least 80,000 people have chronic HCV.[1] Over 50,000 of these will develop cirrhosis. And about 10,000 will develop liver cancer.[2]

To make things worse, there is no vaccine currently available for HCV infection. Happily, there is now a therapy which may make things somewhat better.

It's new Viraferon: interferon α-2b (rbe). The first interferon licensed for chronic hepatitis C specially presented for hepatitis patients.

All in all, it could be a very big answer to a very big problem.

VIRAFERON

INTERFERON ALPHA-2B (rbe)

outweigh the potential hazard to the foetus or nursing infant. **Side Effects**: Elevated liver function tests, reduction in white blood cell, granulocyte and platelet counts have been observed especially at higher doses. Retinal haemorrhages, cotton wool spots and retinal artery or vein obstruction have been observed rarely. The most common adverse effects are 'flu-like' symptoms, leucopenia, thrombocytopenia and CNS effects, which are generally dose-related and reversible and can be ameliorated by dose adjustment. 'Flu-like' symptoms can be alleviated by the use of paracetamol. **Package Quantities**: 10 million IU (2ml) and 25 million IU (5ml) per vial. **Trade Price**: - 10 Million IU (2ml) pack containing 3x10M IU vials: £169.56. - 25 Million IU (5ml) pack containing 2x25M IU vials: £282.60 **Legal Category**: POM. **Product Licence Numbers**: PL 0201/0203-0204. Further information is available from the Product Licence Holder : Schering-Plough Ltd, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW.

References 1. Lau JYN, Williams R. The GP-Specialist Forum, Medical Dialogue 1991; 334: 1- 4.
2. Hepatitis Information for General Practitioners; British Liver Trust.

Date of Preparation: December 1994

NEW HOPE FOR HEPATITIS

Calming the Colitic Colon

P R E D E N E M A

Prednisolone Metasulphobenzoate

Aqueous formulation for the effective treatment of extensive colitis.[1]



P R E D F O A M

Prednisolone Metasulphobenzoate

Metered dose foam formulation provides accurate and consistent dosing for the effective treatment of distal ulcerative proctocolitis.[2]



A complete local management system for ulcerative colitis

Abbreviated Prescribing Information.
Predenema: **Presentation:** Disposable enema 100ml aqueous solution containing prednisolone metasulphobenzoate sodium equivalent to 20 mg of prednisolone. A long tube version is available. **Uses:** Local treatment of ulcerative colitis. **Dosage and Administration:** Adults only: 1 enema nightly for two to four weeks extending the course where a good response is being obtained. **Contraindications, Warnings etc:** Conditions where infection might be masked or healing impaired. Prolonged continuous use is undesirable. There is inadequate evidence of safety in human pregnancy. **Legal categories and Product Licence Numbers:** POM PL 0108/5018 PA 100/7/1. **Packs and NHS Price:** Pack of 7 enemas long tube £9.45. Pack of 10 enemas, standard tube £8.00. Full prescribing information is available on request.
Predfoam Presentation: A foam enema containing prednisolone metasulphobenzoate sodium equivalent to 20mg of prednisolone per metered dose. **Uses:** Treatment of proctitis and ulcerative colitis. **Dosage and Administration:** Adults and Elderly patients: Once or twice daily for two weeks, extending treatment for a further two weeks when a good response is obtained. Children: Not recommended. **Contraindications, Warnings etc:** Conditions where infection might be masked or healing impaired. Prolonged continuous use is undesirable. There is inadequate evidence of safety in human pregnancy. **Legal categories and Product Licence Numbers** POM PL 0108/0101 PA 100/40/1. **Packs and NHS Price** Box containing one 14 dose canister, 14 disposable nozzles and 14 plastic bags:£7.06.Full prescribing information is available on request. **Date of preparation:** October 1994

References. 1. Lee DAH, et al. Rectally administered prednisolone - evidence for a predominantly local action. 1980 Gut;21:215-218. **2.** Foster P, Atkinson M. Clinical evaluation of a prednisolone metasulphobenzoate rectal foam in the treatment of acute distal ulcerative colitis. Data on file.

Pharmax Limited Bexley Kent DA5 1NX

EPFOM0808



Current Opinion in GASTROENTEROLOGY

Subscribe now and stay up-to-date

KEEP UP-TO-DATE WITH CURRENT OPINION

- Every year it is the most reliable source of information in the field.
- Every year the whole field is covered in 6 bi-monthly issues, broken down into 11 subjects.
- Every year within each subject, all the latest developments, expert comment and opinion, and recommended reading are featured.
- Every year **Current Opinion in Gastroenterology** is the only reference you need to keep fully informed.

PRICES FOR ANNUAL SUBSCRIPTION

£84.95 - $134.95 Personal

£169.95 - $269.95 Institutional

£45 - $55 Pre-reg doctors/Residents

Postage: £10 UK £15.75 Eur $11 N Am $37 S Am £25 RoW

EDITOR

T Yamada

1995 SECTIONS AND EDITORS

January
LARGE INTESTINE *MW Mulholland & SF Phillips*
GASTROINTESTINAL INFECTIONS *EC Boedeker*

March
SMALL INTESTINE *DH Alpers, WF Stenson & R Spiller*
NUTRITION *RL Fisher*

May
LIVER *N Gitlin & J Fevery*

July
INFLAMMATORY BOWEL DISEASE *DK Podolsky*
ESOPHAGUS *GNJ Tytgat*

September
PANCREAS *C Owyang*
BILIARY TRACT *RH Moseley*

November
STOMACH AND DUODENUM *ML Schubert*
IMMUNOLOGY *WA Walker*

TO SUBSCRIBE IN N & S AMERICA CONTACT:
Current Science Ltd, 20 North Third Street, Philadelphia, PA 19106, USA.
Tel: 215-574-2210, or Toll Free: 800-552-5866 (US only) Fax: 215-574-3533

IN THE REST OF WORLD CONTACT:
Current Science Ltd, Middlesex House, 34-42 Cleveland Street, London W1P 6LB, UK.
Tel: +44 (0) 171 323 0323, or Freephone: 0800 212530 (UK only) Fax: +44 (0) 171 636 6911.

Everyday people with acid reflux disease can now have new LOSEC 10mg Capsules as maintenance therapy.

LOSEC 10mg od gives a higher remission rate,[1] at a lower cost, than ranitidine 150mg bd. Making it no surprise that LOSEC is taking care of more and more people. Every day.

EVERYDAY PEOPLE TAKE LOSEC

NEW LOSEC® 10mg Capsules

(omeprazole-Astra)

LOSEC® CAPSULES (omeprazole) ABBREVIATED PRESCRIBING INFORMATION (refer to full data sheet before prescribing) **PRESENTATION:** LOSEC Capsules containing 10mg, 20mg or 40mg omeprazole as enteric coated granules with an aqueous based coating. **USES:** Oesophageal reflux disease. Duodenal and benign gastric ulcers (including NSAID-induced). Duodenal ulcer associated with *Helicobacter pylori*. Zollinger-Ellison syndrome. **DOSAGE & ADMINISTRATION:** **Adults (including the elderly):** The usual dose in oesophageal reflux disease and peptic ulcer is 20mg once daily, increasing to 40mg once daily in severe or refractory cases, if required. **Oesophageal reflux disease:** Healing: 20mg daily for 4 weeks. Continue for further 4-8 weeks if required. **Maintenance in acid reflux disease:** LOSEC 10mg daily. Increase to 20mg daily If symptoms return. **Duodenal ulcer (DU):** Healing: 20mg daily for 4 weeks. **DU maintenance:** LOSEC 10mg daily increasing to 20mg daily if symptoms return. **DU associated with *Helicobacter pylori*:** Usual dose is LOSEC 40mg daily with amoxycillin 1.5g daily (750mg b.d.) for 2 weeks. Up to 2g/day of amoxycillin has been used in clinical studies. **Benign Gastric Ulcer:** 20mg daily for 8 weeks. **Zollinger-Ellison Syndrome:** 60mg daily as long as clinically indicated. Individually adjust within range 20-120mg daily. If in excess of 80mg daily give in 2 equal divided doses. **Renal impairment:** No dose adjustment needed. **Hepatic impairment:** Adjust dose (maximum daily dose 20mg). **Children:** No experience of use. **CONTRA-INDICATIONS, WARNINGS, ETC:** No known contra-indications. In gastric ulcer, exclude malignancy before starting therapy. Avoid in pregnancy unless no safer alternative. Discontinue breast feeding if LOSEC is considered essential. **Side effects:** LOSEC is well tolerated. Adverse reactions are generally mild and reversible (relationship to LOSEC not established in many cases). They include diarrhoea, headaches, skin disorders and in isolated cases, angioedema, musculoskeletal disorders, fatigue, insomnia, dizziness, blurred vision, vertigo, paraesthesia, liver enzyme and haematological changes. LOSEC can delay the elimination of phenytoin and warfarin. **PHARMACEUTICAL PRECAUTIONS:** Use within three months of opening. Store below 30°C. Replace cap firmly after use. Dispense in original container. **LEGAL CATEGORY:** POM. **FURTHER INFORMATION:** ***Helicobacter pylori*** (Hp) is associated with acid peptic and ulcer disease, contributing to gastritis and ulcer recurrence. In patients known to be allergic to amoxycillin, clarithromycin may be a useful alternative in dual therapy. Omeprazole 40mg daily, amoxycillin 1500mg daily and metronidazole 1200mg daily for 14 days achieved an overall Hp eradication rate of 89% (96% in metronidazole-sensitive isolates). **PACKAGE QUANTITIES:** 10mg: bottles of 7 capsules £4.99, bottles of 28 capsules £19.95. 20mg: bottles of 7 capsules, £8.86, bottles of 28 capsules, £35.45; 40mg: bottles of 7 capsules £17.72, bottles of 14 capsules £35.45.

PRODUCT LICENCE NUMBERS:
PL 0017/0337- LOSEC Capsules 10mg.
PL 0017/0238 - LOSEC Capsules 20mg.
PL 0017/0320 - LOSEC Capsules 40mg.

Reference:
1. Hallerbäck B, *et al.* 9th Asian-Pacific Congress of Gastroenterology & 6th Asian-Pacific Congress of Digestive Endoscopy, Bangkok, Thailand. Nov 29-Dec 3 1992; 90: Abstract FP-88.

ASTRA
Astra Pharmaceuticals

For further information contact the **PRODUCT LICENCE HOLDER:** Astra Pharmaceuticals Ltd, Home Park, Kings Langley, Herts WD4 8DH. Tel: (0923) 266191.

Date of preparation: September 1994 LOS/ADV 044